Traduction de «response to treatment in clinical » (Néerlandais → Français) :

Referenties (4) Louis Harris Interactive research, 2002 (14) Mulhall JP et al. Erectile dysfunction: Monitoring response to treatment in clinical practice-recommendations of an international study panel.
Références : (4) Louis Harris Interactive research, 2002 (14) Mulhall JP et al. Erectile dysfunction: Monitoring response to treatment in clinical practice-recommendations of an international study panel.

Unit I Unit I is responsible for the tasks of the secretariat of the commission for the establishment of retail pharmacies, of the secretariat of the commission for the recognition of pharmacists-clinical biologists, of the retail pharmacies registry and plays an important role in the problems of products in the “grey area” (these are “borderline” products whose exact status has to be determined: is it a medicine or not?).
Unit I Unit I is responsible for the tasks of the secretariat of the commission for the establishment of retail pharmacies, of the secretariat of the commission for the recognition of pharmacists-clinical biologists, of the retail pharmacies registry and plays an important role in the problems of products in the “grey area” (these are “borderline” products whose exact status has to be determined: is it a medicine or not?).

The R&D (research and development) department of the FAMHP is responsible for the evaluation and approval of clinical research activities, ranging from the first “use” (concept) to extensive trials with medicines that are developed and carried out by university and other research centres and by the pharmaceutical industry.
The R&D (research and development) department of the FAMHP is responsible for the evaluation and approval of clinical research activities, ranging from the first “use” (concept) to extensive trials with medicines that are developed and carried out by university and other research centres and by the pharmaceutical industry.

The clinical significance of heterogeneous glycopeptide intermediate S. aureus (hGISA; borderline susceptible strains) is unclear, although recent data suggest that the response to the glycopeptide therapy administered to patients infected by such variants can be poor.
La signification clinique de S. aureus intermédiaire aux glycopeptides hétérogènes (hGISA; les souches sensibles limites) est peu claire bien que les données récentes suggèrent que la réponse à la thérapie aux glycopeptides des patients infectés par de telles variantes peut être insuffisante.

- Regulatory feedback expected in Q4 2010 Q4 2008 Approved Q3 2010 - Clinical trials to address US Food and Drug Administration (FDA) complete response letter (October 2009) completed in Q3 and data generated from these trials was submitted to the FDA in late September
2010 T4 2008 Autorisé T3 2010 - Essais cliniques pour répondre à la «complete response letter» de la FDA (oct. 2009) achevés au T3 et données soumises à fin septembre à la FDA

Novartis submitted in August 2009 answers to a Complete Response letter received earlier in the year from the FDA requesting additional information on the submission’s clinical and CMC (Chemistry Manufacturing and Control) sections.
Novartis a soumis en août 2009 des réponses à une «Complete Response letter» envoyée en début d’année par la FDA et demandant des informations complémentaires sur les sections Clinique et CMC (fabrication chimique et contrôle) du dossier.

Screening for GISA should be performed by means of the agar screen technique on clinical isolates of MRSA, at least when dealing with patients failing to respond to glycopeptide treatment 33,34 .
Le dépistage de GISA devrait être fait par la technique de dépistage sur gélose sur les isolats cliniques de MRSA au moins chez les patients ne réagissant pas au traitement par glycopeptide 33,34 .

However, an increased risk of clinical failure with nasal treatment of multi-site MRSA colonisation has been associated with lowlevel resistance in one study 31 .
Cependant, un risque accru d'échec clinique dans le traitement nasal de la colonisation multi-site par MRSA a été associé, dans une étude 31 , à la résistance de faible niveau.

3.3.2 Determination of susceptibility to vancomycin Homogeneous glycopeptide intermediate resistant strains (vancomycin MIC of 8 mg/L or teicoplanin 16 mg/L) have been related to clinical failure of glycopeptide treatment.
3.3.2 Détermination de la sensibilité à la vancomycine Un lien a été établi entre les souches résistantes intermédiaires glycopeptides homogènes (vancomycin MIC de 8 mg/L ou teicoplanine 16 mg/L) et l'échec clinique du traitement au glycopeptide.

Future of Independent Academic Clinical Research in Europe, Koninklijke academie voor Geneeskunde in samenwerking met European Organisation for Research and Treatment of Cancer (EORTC) , 2 september 2010;
Future of Independent Academic Clinical Research in Europe, Académie royale de médecine en collaboration avec l’European Organisation for Research and Treatment of Cancer (EORTC), 2 septembre 2010 ;